A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer
NCT ID: NCT05945927
Last Updated: 2025-10-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
178 participants
OBSERVATIONAL
2023-09-13
2025-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer
NCT03084939
Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy
NCT06125834
Study of the Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Participants With Locally Advanced Inoperable or Metastatic HER2+ Breast Cancer
NCT03153163
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
NCT06210776
Tyrosine Kinase Inhibitors (TKIs) in Trastuzumab Emtansine (T-DM1) Resistant HER2-positive Metastatic Breast Cancer: A Real-world Study
NCT05231863
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants with HER2-positive Advanced Breast Cancer
Participants will be prospectively followed from the index date (the first treatment of T-DM1) for up to 1 year.
Trastuzumab emtansine
Trastuzumab emtansine will be administered as per local clinical practice and local labeling.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Trastuzumab emtansine
Trastuzumab emtansine will be administered as per local clinical practice and local labeling.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Had prior treatment for breast cancer which must contain a taxane and trastuzumab
* Get the treatment of T-DM1 for the first time after diagnosis of breast cancer
Exclusion Criteria
* Has been previously treated with T-DM1 before current clinical visit
* Currently participating in any clinical trials
* Previously participated in any clinical trials investigating anti-HER2 drug within 1 year of the initiation of T-DM1
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Anyang Tumor Hosptial
Anyang, , China
Affiliated Hospital of Hebei University
Baoding, , China
Cancer Hospital Chinese Academy of Medical Sciences.
Beijing, , China
Beijing Hospital
Beijing, , China
the First Hospital of Jilin University
Changchun, , China
West China Hospital of Sichuan University
Chengdu, , China
Fujian Cancer Hospital
Fuzhou, , China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, , China
The Affiliated Cancer Hospital of Guizhou Medical University
Guiyang, , China
Harbin Medical University Cancer Hospital
Harbin, , China
Anhui Province Cancer Hospital
Hefei, , China
Jiangmen Central Hospital
Jiangmen, , China
The First Affiliated Hospital Of Shandong First Medical University
Jinan, , China
Dongyang People's Hospital
Jinhua, , China
The Third Hospital of Nanchang
Nanchang, , China
Nanjing Gulou Hospital
Nanjing, , China
Guangxi Cancer Hospital of Guangxi Medical University
Nanning, , China
Affiliated Hospital of Nantong University
Nantong, , China
Ningbo No.2 Hospital
Ningbo, , China
China Medical University (CMU) First Affiliated Hospital
Shenyang, , China
Cancer Hospital Chinese Academy of Medical Sciences Shenzhen Center
Shenzhen, , China
Shanxi Provincial Cancer Hospital
Taiyuan, , China
Tianjin Cancer Hospital
Tianjin, , China
Cancer Hospital Affliated to Xinjiang Medical University
Ürümqi, , China
Weifang People's Hospital
Weifang, , China
Union Hospital of Tongji Medical College, Dept. of Cancer Center
Wuhan, , China
Hubei Cancer Hospital
Wuhan, , China
First Affiliated Hospital of Medical College of Xi'an Jiaotong University
Xi'an, , China
Yibin Second People's Hospital
Yibin, , China
Zhejiang Cancer Hospital
Zhejiang, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML44675
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.